ライフサイエンスコーパス: high-dose chemotherapy

1 acute leukaemia patients and those receiving high dose chemotherapy.

2 cer patients from myelosuppression caused by high-dose chemotherapy.

3 or the bone marrow of 45 patients undergoing high-dose chemotherapy.

4 famide program, and six experienced CR after high-dose chemotherapy.

5 hs were attributable to the toxic effects of high-dose chemotherapy.

6 factor was administered after each cycle of high-dose chemotherapy.

7 ocytopenia, and anemia in patients receiving high-dose chemotherapy.

8 or eliminate the period of neutropenia after high-dose chemotherapy.

9 patients treated with either conventional or high-dose chemotherapy.

10 n bioreactors for 12 days, and infused after high-dose chemotherapy.

11 s effect was seen only in patients receiving high-dose chemotherapy.

12 e myeloma, including those who relapse after high-dose chemotherapy.

13 and accelerate hematopoietic recovery after high-dose chemotherapy.

14 herapy, and, if they responded to treatment, high-dose chemotherapy.

15 marrow transplantation in patients receiving high-dose chemotherapy.

16 y mediastinal localization on the outcome of high-dose chemotherapy.

17 is a complete response prior to or following high-dose chemotherapy.

18 total body irradiation (TBI) and multiagent, high-dose chemotherapy.

19 ic progenitor cells and reconstitution after high-dose chemotherapy.

20 ble subset of patients seems to benefit from high-dose chemotherapy.

21 on of the blood-brain barrier and the use of high-dose chemotherapy.

22 e conditioned with total body irradiation or high-dose chemotherapy.

23 nd inferior responses to both induction- and high-dose chemotherapy.

24 plus ifosfamide plus cisplatin preceded the high-dose chemotherapy.

25 e, but cannot be cured with conventional and high-dose chemotherapy.

26 udy of patients with breast cancer receiving high-dose chemotherapy, adjunct electroacupuncture was m

27 All patients were then treated with high-dose chemotherapy alone and observed for outcome.

28 ancy outcome among patients who had received high-dose chemotherapy alone or with total-body irradiat

29 Second- and third-line programs, including high-dose chemotherapy, also have curative potential.

30 d the liver or bone marrow were treated with high-dose chemotherapy and allogeneic PBPC transplantati

31 ntensive, involved-field radiotherapy before high-dose chemotherapy and ASCR, which was incorporated

32 of the earliest trials pioneering the use of high-dose chemotherapy and autologous bone marrow transp

33 iastinum can achieve prolonged PFS following high-dose chemotherapy and autologous hematopoietic cell

34 The addition of high-dose chemotherapy and autologous hematopoietic stem

35 High-dose chemotherapy and autologous hematopoietic stem

36 e 1/2 study in lymphopenic individuals after high-dose chemotherapy and autologous hematopoietic stem

37 Twenty-eight patients were given high-dose chemotherapy and autologous PBPCs plus culture

38 Cytopenia after high-dose chemotherapy and autologous stem cell reinfusi

39 iple myeloma cells in clinical samples after high-dose chemotherapy and autologous stem cell transpla

40 High-dose chemotherapy and autologous stem-cell transpla

41 and vomiting (CINV) for patients undergoing high-dose chemotherapy and autologous stem-cell transpla

42 d as maintenance treatment immediately after high-dose chemotherapy and autologous stem-cell transpla

43 udy was performed to evaluate the outcome of high-dose chemotherapy and autologous transplantation in

44 formulations to support patients undergoing high-dose chemotherapy and BMT are needed.

45 ressive non-Hodgkin lymphoma (NHL) following high-dose chemotherapy and CD34+-selected hematopoietic

46 Intensive management with primary high-dose chemotherapy and concurrent periocular carbopl

47 eral blood stem cells (PBSCs) mobilized with high-dose chemotherapy and hematopoietic growth factors

48 related mortality both in patients receiving high-dose chemotherapy and in those receiving moderately

49 final 3 days of cytokine therapy and, after high-dose chemotherapy and infusion of PBPCs, patients r

50 the severe immunodeficiency associated with high-dose chemotherapy and led to the induction of clini

51 patients with poor-prognosis lymphomas with high-dose chemotherapy and marrow or peripheral stem-cel

52 High-dose chemotherapy and multimodality treatment seeme

53 The patient had a complete response to high-dose chemotherapy and no major acute complications.

54 BMT patients receive high-dose chemotherapy and often radiation, as well.

55 melphalan should thus be considered standard high-dose chemotherapy and ongoing randomised studies wi

56 ) to patients with breast cancer who undergo high-dose chemotherapy and PBPC transplantation was inve

57 T cells in breast cancer patients undergoing high-dose chemotherapy and peripheral blood stem cell tr

58 o intensify consolidation with triple-tandem high-dose chemotherapy and peripheral-blood stem-cell re

59 herapeutic strategies in patients undergoing high-dose chemotherapy and PSCT.

60 rly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at

61 teria organs, followed in 6 months by either high-dose chemotherapy and stem cell transplantation for

62 The combination of high-dose chemotherapy and stem cell transplantation is

63 The remaining seven received high-dose chemotherapy and stem-cell infusion.

64 ed CAF alone and those who received CAF plus high-dose chemotherapy and stem-cell transplantation.

65 her progress is being reported on the use of high-dose chemotherapy and stem-cell transplants, althou

66 story of myelodysplastic syndrome, underwent high-dose chemotherapy and total body irradiation prior

67 Oral mucositis is a common toxicity of high-dose chemotherapy and upper mantle head and neck ra

68 been viewed as an unavoidable consequence of high-dose chemotherapy and/or radiation.

69 py (fractionated total-body irradiation plus high-dose chemotherapy) and after autologous hematopoiet

70 Fifty of the 53 patients commenced high-dose chemotherapy, and 49 patients completed all fo

71 tage and advanced epithelial ovarian cancer, high-dose chemotherapy, and biologic and gene therapy.

72 ea under the curve >/= 4 mg/mL per minute or high-dose chemotherapy, and for pediatric patients who r

73 his patient population that progressed after high-dose chemotherapy, and had not received prior pacli

74 sporine, total body irradiation, infections, high-dose chemotherapy, and recurrent malignancies.

75 py regimens, new trials exploring multicycle high-dose chemotherapy, and the development of prognosti

76 zed trials was not significantly improved by high-dose chemotherapy; any benefit from high doses was

77 e, and active, the use of multiple cycles of high-dose chemotherapy as front-line treatment remains e

78 High-dose chemotherapy as initial salvage chemotherapy a

79 otal of 56 consecutive patients treated with high-dose chemotherapy as part of this program.

80 ve disease (VOD) is a common complication of high-dose chemotherapy associated with bone marrow trans

81 undred eighty-four patients received salvage high-dose chemotherapy at Indiana University (Indianapol

82 The role of salvage treatments and high-dose chemotherapy at relapse is not clear.

83 cell rescue was given after the last dose of high-dose chemotherapy, at least 24 h after melphalan in

84 reated, measurable MM, who were eligible for high-dose chemotherapy-autologous stem-cell transplantat

85 cell transplantation (HCT), patients receive high-dose chemotherapy before transplantation and experi

86 ase who suffer from T-cell suppression after high-dose chemotherapy but are not deficient in NK cells

87 tly activated intergroup randomized study of high-dose chemotherapy compared with conventional dose c

88 L may display an increased susceptibility to high-dose chemotherapy compared with other types of B-ce

89 gave 173 patients two consecutive courses of high-dose chemotherapy consisting of 700 mg of carboplat

90 nts with advanced breast cancer treated with high-dose chemotherapy, consisting of cisplatin 250 mg/m

91 urrent triple antiemetic pharmacotherapy and high-dose chemotherapy (cyclophosphamide, cisplatin, and

92 risk-adapted CSI followed by four cycles of high-dose chemotherapy (cyclophosphamide, cisplatin, and

93 followed 45 consecutive women who underwent high-dose chemotherapy (cyclophosphamide/cisplatin/BCNU)

94 ms of the study were to determine 1) whether high-dose chemotherapy decreases concentrations of major

95 protect mice, but not cancer cells, against high-dose chemotherapy [differential stress resistance (

96 We use this framework to show how high-dose chemotherapy engenders opposing evolutionary p

97 ed with marker-dependent, early-intervention high-dose chemotherapy experienced longer survival (P =

98 emotherapy, the responding patients received high-dose chemotherapy followed by ASCT.

99 have shown the feasibility of administering high-dose chemotherapy followed by autologous bone marro

100 t cancer are the most frequent recipients of high-dose chemotherapy followed by autologous hematopoie

101 Twelve patients were treated with high-dose chemotherapy followed by autologous stem-cell

102 chemotherapy, 14 patients were treated with high-dose chemotherapy followed by autologous stem-cell

103 High-dose chemotherapy followed by hematopoietic stem ce

104 Twenty-four patients received high-dose chemotherapy followed by infusion of the cultu

105 F) in 29 breast cancer patients treated with high-dose chemotherapy followed by PBPC reinfusion.

106 All patients underwent the same high-dose chemotherapy followed by reinfusion of PBCs.

107 f patients treated with sequential cycles of high-dose chemotherapy, followed by autologous PBPC infu

108 High-dose chemotherapy, followed by hematopoietic stem c

109 ceiving chemotherapy for acute leukaemia and high dose chemotherapy for solid tumours.

110 Controversy has surrounded the use of high-dose chemotherapy for breast cancer for more than a

111 authors review the main research results of high-dose chemotherapy for breast cancer in 2002 to 2003

112 he number of transfusions required following high-dose chemotherapy for breast cancer.

113 s treated uniformly in prospective trials of high-dose chemotherapy for four to nine positive axillar

114 ologous recipients hospitalized after recent high-dose chemotherapy for multiple myeloma.

115 chemotherapy should help clarify the role of high-dose chemotherapy for the treatment of this disease

116 /m(2) (5 mCi/m(2)) in patients who had prior high-dose chemotherapy (group 2), and at 0.370 GBq/m(2)

117 The immunosuppression provided by high-dose chemotherapy has been studied to address treat

118 High-dose chemotherapy has long been advocated as a mean

119 Early results of high-dose chemotherapy have been released, and the role

120 Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options.

121 Although surgery, radiation and high-dose chemotherapy have led to increased survival, m

122 = 68), or amyloidosis (n = 2), treated with high-dose chemotherapy (HDC) and ASCT without transfusio

123 luated the outcomes of patients who received high-dose chemotherapy (HDC) and autologous hematopoieti

124 ective study to determine the feasibility of high-dose chemotherapy (HDC) and autologous stem-cell re

125 The controversy surrounding high-dose chemotherapy (HDC) for breast cancer seems to

126 andomized study reported by Bezwoda et al of high-dose chemotherapy (HDC) for treatment of metastatic

127 and platelet recovery for patients receiving high-dose chemotherapy (HDC) supported with peripheral-b

128 t conventional-dose chemotherapy or from the high-dose chemotherapy (HDC) used for the transplant pro

129 Adjuvant high-dose chemotherapy (HDC) with autologous hematopoiet

130 ed adjuvant chemotherapy regimen followed by high-dose chemotherapy (HDC) with autologous hematopoiet

131 fulness of a treatment regimen that included high-dose chemotherapy (HDC) with autologous stem-cell r

132 High-dose chemotherapy (HDC) with autologous stem-cell t

133 High-dose chemotherapy (HDC) with peripheral-blood proge

134 women with advanced breast cancer undergoing high-dose chemotherapy (HDC).

135 combination with interleukin-2 (IL-2) after high-dose chemotherapy (HDC)/stem-cell rescue (SCR).

136 ow of patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous bone marrow

137 t survival outcomes of patients treated with high-dose chemotherapy (HDCT) and peripheral-blood stem-

138 To investigate the role of high-dose chemotherapy (HDCT) as first-line treatment in

139 prognostic variables for patients undergoing high-dose chemotherapy (HDCT) as salvage modality for ge

140 Most of the data about high-dose chemotherapy (HDCT) for metastatic breast canc

141 the current role and future perspectives of high-dose chemotherapy (HDCT) in the management of advan

142 dose-dense approach consolidated by up-front high-dose chemotherapy (HDT) and autologous stem-cell tr

143 tumor were treated with one or two cycles of high-dose chemotherapy (HDT) followed by autologous HSCR

144 High-dose chemotherapy (HDT) plus autologous stem cell t

145 o of our center's programs that incorporated high-dose chemotherapy (high-dose carboplatin plus etopo

146 e survival advantage is apparent in favor of high-dose chemotherapy in both high-risk primary and met

147 th the 62% 5-year survival rate after tandem high-dose chemotherapy in first-line salvage of metastat

148 omparing conventional-dose chemotherapy with high-dose chemotherapy in patients in the early stages o

149 the preferred means of stem cell support for high-dose chemotherapy in recent years.

150 r the randomized studies evaluating adjuvant high-dose chemotherapy in the early stages of breast can

151 s of disease, and chemotherapy, particularly high-dose chemotherapy in the first-line and salvage set

152 The role of high-dose chemotherapy in the management of women with b

153 phamide, mitoxantrone, etoposide regimen for high-dose chemotherapy in women with high-risk primary b

154 High-dose chemotherapy increasingly is being employed to

155 High-dose chemotherapy increasingly is being used for th

156 High dose chemotherapy induced the phosphorylation of p5

157 emission with induction therapy with AFM and high-dose chemotherapy is increased for hormone receptor

158 High-dose chemotherapy is increasingly being employed to

159 High-dose chemotherapy is increasingly being employed to

160 High-dose chemotherapy is increasingly utilized for the

161 values can alter the outcome from one where high-dose chemotherapy is optimal to one where using the

162 The role of high-dose chemotherapy is still debated.

163 ity in patients with low tumor burdens after high-dose chemotherapy, limited use of low-dose oral eto

164 There is a hint that high-dose chemotherapy may play a role in relapsed patie

165 Radiation and high-dose chemotherapy may render women with cancer prem

166 t undermines predictions that limited use of high-dose chemotherapy might be minimally leukemogenic,

167 The effect of high-dose chemotherapy on overall survival was not stati

168 x vivo expansion of stem cells to be used in high-dose chemotherapy or gene therapy.

169 hat oncogenic translocations occurring after high-dose chemotherapy or radiation could be prevented b

170 In the HIV-negative setting, high-dose chemotherapy or stem cell transplantation is a

171 After high-dose chemotherapy, patients who had peripheral-bloo

172 Salvage high-dose chemotherapy plus a stem-cell transplant was r

173 ntenance chemotherapy in conventional doses, high-dose chemotherapy plus autologous stem-cell transpl

174 High-dose chemotherapy plus autologous stem-cell transpl

175 ree and overall survival have been seen with high-dose chemotherapy plus autologous stem-cell transpl

176 o progression of the disease (9.6 months for high-dose chemotherapy plus hematopoietic stem cells and

177 these, 110 patients were assigned to receive high-dose chemotherapy plus hematopoietic stem cells and

178 cted a randomized trial in which we compared high-dose chemotherapy plus hematopoietic stem-cell resc

179 r tumors are potentially curable by means of high-dose chemotherapy plus hematopoietic stem-cell resc

180 High-dose chemotherapy poses considerable challenges to

181 Treatment includes high-dose chemotherapy preceded by surgical resection an

182 osfamide, and cisplatin, single agents, or a high-dose chemotherapy program.

183 ipheral blood progenitor cells (PBPCs) after high-dose chemotherapy rapidly restores multilineage hem

184 refractory myeloma (76 with a relapse after high-dose chemotherapy) received oral thalidomide as a s

185 of which were for patients who received the high-dose-chemotherapy regimen.

186 rent or poor-prognosis CNS malignancies with high-dose chemotherapy regimens followed by autologous m

187 The use of high-dose chemotherapy regimens is limited by the severi

188 cluded an open-label randomised arm in which high-dose chemotherapy regimens were compared.

189 of tumor cells in the autologous graft, new high-dose chemotherapy regimens, new trials exploring mu

190 arrow toxicity, the limiting factor for most high-dose chemotherapy regimens.

191 rincipal element of supportive care for many high-dose chemotherapy regimens.

192 eled antibodies, total-body irradiation, and high-dose chemotherapy remain disease free.

193 High-dose chemotherapy remains a valid research strategy

194 to 36 months with conventional therapy, but high-dose chemotherapy resulted in better outcomes in a

195 ials have suggested a survival advantage for high-dose chemotherapy, several randomised studies have

196 The most relevant alternatives to WBRT are high-dose chemotherapy supported by autologous stem cell

197 mbining surgery, craniospinal radiation, and high-dose chemotherapy, that often cause disabling neuro

198 carbazine) followed by a novel consolidation high-dose chemotherapy (thiotepa, busulfan, cyclophospha

199 sease-free survival among patients receiving high-dose chemotherapy, those undergoing autologous bone

200 od stem-cell transplantation (referred to as high-dose chemotherapy) to women with metastatic disease

201 ous bone marrow transplantation as part of a high-dose chemotherapy treatment for advanced cancer wer

202 potential for delivery of rapidly sequenced high-dose chemotherapy treatments rescued with autologou

203 High-dose chemotherapy using diverse regimens with hemat

204 High-dose chemotherapy using high-dose etoposide as ther

205 High-dose chemotherapy was associated with significant m

206 ved chemotherapy; multimodality treatment or high-dose chemotherapy was not associated with statistic

207 Partial responders then received immediate high-dose chemotherapy, whereas those who achieved compl

208 These advances were: introduction of high dose chemotherapy, which appears to be superior to

209 Patients were ineligible for high-dose chemotherapy, which would put them at risk for

210 may affect the outcome of patients receiving high dose chemotherapy with autologous transplantation o

211 ators have suggested that consolidation with high dose chemotherapy with or without radiation therapy

212 High-dose chemotherapy with a combination of vincristine

213 High-dose chemotherapy with ABMT is promising in patient

214 Meta-analysis of the use of high-dose chemotherapy with autologous hematopoetic stem

215 The impact of high-dose chemotherapy with autologous hematopoietic cel

216 ncer is currently the primary indication for high-dose chemotherapy with autologous hematopoietic pro

217 High-dose chemotherapy with autologous hematopoietic ste

218 Meta-analysis of data on the use of high-dose chemotherapy with autologous hematopoietic ste

219 High-dose chemotherapy with autologous marrow or stem ce

220 a better chance of long-term remission with high-dose chemotherapy with autologous stem cell rescue

221 High-dose chemotherapy with autologous stem cell transpl

222 High-dose chemotherapy with autologous stem cell transpl

223 ich patients are most likely to benefit from high-dose chemotherapy with autologous stem-cell rescue.

224 who were not eligible for or had experienced high-dose chemotherapy with autologous stem-cell transpl

225 Purpose The benefit of high-dose chemotherapy with autologous stem-cell transpl

226 High-dose chemotherapy with autologous stem-cell transpl

227 l agents, conventional cytotoxic agents, and high-dose chemotherapy with autotransplantation (modalit

228 High-dose chemotherapy with autotransplantation, which h

229 Substantial interest in supporting high-dose chemotherapy with bone marrow or autologous he

230 There may be a role for high-dose chemotherapy with bone marrow rescue in relaps

231 We aimed to assess event-free survival after high-dose chemotherapy with busulfan and melphalan compa

232 include the first randomized trial comparing high-dose chemotherapy with conventional-dose chemothera

233 r the same adjuvant chemotherapy followed by high-dose chemotherapy with cyclophosphamide and thiotep

234 The patients underwent high-dose chemotherapy with cyclophosphamide, carboplati

235 ntial economic benefit in patients receiving high-dose chemotherapy with either bone marrow or periph

236 High-dose chemotherapy with haemopoietic stem-cell rescu

237 High-dose chemotherapy with hematopoietic progenitor cel

238 sion were randomized to immediate or delayed high-dose chemotherapy with hematopoietic stem-cell supp

239 re groups of patients who might benefit from high-dose chemotherapy with hematopoietic support.

240 age, 1.8 years; range, 0.4 to 7.9) received high-dose chemotherapy with or without irradiation and B

241 nge, 0.9 to 3.2 years) with MPS I H received high-dose chemotherapy with or without radiation followe

242 Before high-dose chemotherapy with or without stem cell rescue

243 High-dose chemotherapy with peripheral blood stem cell t

244 dation of his second remission, he underwent high-dose chemotherapy with peripheral blood stem cell t

245 apy, for patients with disseminated disease, high-dose chemotherapy with peripheral blood transplanta

246 lvage chemotherapy with tandem transplant of high-dose chemotherapy with peripheral stem cell rescue.

247 The efficacy of high-dose chemotherapy with progenitor-cell rescue for w

248 Numerous randomized trials have compared high-dose chemotherapy with standard-dose chemotherapy i

249 The role of chemotherapy, radiation, and high-dose chemotherapy with stem cell rescue in the mana

250 Conclusive evidence for the efficacy of high-dose chemotherapy with stem cell rescue is lacking

251 ed relapse; if surgery is not feasible, then high-dose chemotherapy with stem cell transplant in an e

252 ons, including reduced-dose radiotherapy and high-dose chemotherapy with stem-cell rescue, aiming at

253 older than 12 months varied; most receiving high-dose chemotherapy with stem-cell rescue.

254 Administering four consecutive cycles of high-dose chemotherapy with stem-cell support after surg

255 High-dose chemotherapy with stem-cell support produced p

256 90 average risk) followed by four cycles of high-dose chemotherapy with stem-cell support.

257 ol into conventional protocols or the use of high-dose chemotherapy with stem-cell transplants.

258 atin combination chemotherapy and subsequent high-dose chemotherapy with tandem transplantation.

259 or without second-look surgery proceeded to high-dose chemotherapy with thiotepa and etoposide and a

260 In patients given high-dose chemotherapy, with or without radiation, for t

261 Most patients received high-dose chemotherapy without radiation for pretranspla

262 High-dose chemotherapy without stem cell rescue has been

263 ssibility of decreasing disease activity but high-dose chemotherapy without stem cell rescue having a

264 cells concomitant with the administration of high-dose chemotherapy would reduce the duration of abso